Latest News for ELTP
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
Elite Pharmaceuticals OTCMKTS: ELTP reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.
Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELTP.
U.S. House Trading
No House trades found for ELTP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.